Semaglutide Acetate NEW
| Price | $213 | $463 | $662 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-11-10 |
Product Details
| Product Name: Semaglutide Acetate | CAS No.: 1997361-85-9 |
| Purity: 99.45% | Supply Ability: 10g |
| Release date: 2025/11/10 |
Product Introduction
Bioactivity
| Name | Semaglutide Acetate |
| Description | Semaglutide Acetate is a GLP-1R agonist (EC50=6.2 pM) with long-acting, selective, competitive, and oral efficacy. Semaglutide acetate can be used in the study of type 2 diabetes. |
| In vitro | METHODS: SH-SY5Y cells were treated with Semaglutide acetate (0, 1, 10, and 100 nM) for 24 hours, and cell viability was measured using MTT assay. RESULTS: Semaglutide acetate significantly increased the survival rate of SH-SY5Y cells. [1] METHODS: SH-SY5Y cells were treated with Semaglutide acetate for 48 hours, and target protein expression was detected using Western Blot. RESULTS: Semaglutide acetate increased the expression of autophagy-related proteins such as LC3II, Atg7, Beclin-1, and P62, inhibited Bax and up-regulated Bcl-2, thereby protecting nerve cells by enhancing autophagy and inhibiting apoptosis. [2] METHODS: Oral squamous cell carcinoma (OSCC) cells were treated with Semaglutide acetate (5-40 μM) for 48 hours, and target protein expression was detected using Western Blot. RESULTS: Semaglutide acetate up-regulated E-cadherin and down-regulated Vimentin, activated P38 MAPK signaling pathway (p-P38 expression increased), and induced cell apoptosis. [3] |
| In vivo | METHODS: To study the antitumor activity of Semaglutide Acetate, Semaglutide (3 μmol/kg) was subcutaneously injected into nude mice with oral squamous cell carcinoma (OSCC) transplanted tumors for 3 weeks per week for 3 consecutive weeks. RESULTS: Semaglutide Acetate significantly inhibited the growth of oral squamous cell carcinoma (OSCC) xenografts in nude mice, down-regulated the proliferation markers Ki67 and PCNA, up-regulated the pro-apoptotic protein Bax and down-regulated the anti-apoptotic protein Bcl-xL. Tumor cell apoptosis was induced by activation of P38 MAPK pathway. [3] METHODS: To investigate the effect of Semaglutide Acetate on Parkinson's disease, a mouse model of chronic MPTP-induced Parkinson's disease was induced by intraperitoneal injection of Semaglutide (25 nmol/kg) every 2 days for 30 consecutive days. RESULTS: Semaglutide Acetate improved chronic MPTP-induced Parkinson's disease and motor dysfunction in mice. Semaglutide acetate increased the number of tyrosine (TH) -positive neurons in the substantia nigra, reduced α-synuclein aggregation and glial cell activation, and decreased the level of oxidative stress marker 4-HNE. [4] METHODS: To study the effect of Semaglutide Acetate on fatty liver disease, metabolic dysfunction associated fatty liver disease (MASLD) mice were subcutaneously injected with Semaglutide (25 μg/kg, 100 μg/kg) once a week for 11 weeks. RESULTS: Semaglutide Acetate reduced body weight, blood glucose, serum liver enzymes (ALT, AST, and AP), reduced intrahepatic triglyceride deposition, ameliorated hepatic steatosis and hepatocyte balloon-like degeneration, and down-regulated de novo lipogenesis markers Acaca and Scd1. [5] |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 0.05 mg/mL (insoluble) DMSO : 4.17 mg/mL (1 mM), Sonication and heating are recommended. |
| Keywords | Semaglutide Acetate | GlucagonReceptor | Glucagon Receptor | GLP-1 |
| Inhibitors Related | PF-06882961 Tris | PF-06882961 | Secretin (33-59), rat | (S, R)-LSN 3318839 | NNC 92-1687 | Adomeglivant | Bay 55-9837 acetate | 6α-Methylprednisolone 21-hemisuccinate sodium salt | Orforglipron | Tirzepatide Acetate(2023788-19-2 free base) | LSN3318839 | HAEGTFTSDVS acetate |
| Related Compound Libraries | Membrane Protein-targeted Compound Library | Peptide Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1G |
VIP2Y
|
Taizhou Creating Bio-pharm co., ltd.
|
2025-07-15 | |
| $0.00/1kg |
VIP2Y
|
Chongqing Zhihe Biopharmaceutical Co., Ltd.
|
2025-03-02 | |
| $0.00/1G |
VIP5Y
|
Sinoway Industrial co., ltd.
|
2025-10-11 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY